Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences

A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.

Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam

Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.

Medtronic Delivers Favorable Outcome on Guardian Connect

Tandem Diabetes Care

Tandem Diabetes stock skidded Monday as investors questioned whether the medical devices maker could catch up to industry leader Medtronic in diabetes treatment using a pump and monitor.
The post How The David Of Diabetes Devices Is Taking On Goliath — And Why Shares Dipped appeared first on Investor's Business Daily.

How The David Of Diabetes Devices Is Taking On Goliath — And Why Shares Dipped

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Boston Scientific

Royal Philips

The Food and Drug Administration likely won't pull medical devices coated in chemotherapy drug paclitaxel from the market, an analyst said Thursday. But it could require additional studies.

Why The FDA Likely Won't Pull These Medical Devices From The Market

Medtronic PLC (NYSE: MDT) has earned a bullish review from Wells Fargo Securities, which premised its optimistic outlook on the company's growth prospects.

Wells Fargo: Medtronic An Accelerating Growth Story Trading At A Discount

General Electric

Keurig Dr Pepper Inc

Phillips 66

The largest Insider Buys this week were for Medtronic PLC, General Electric Co., Keurig Dr Pepper Inc. and Phillips 66.

Weekly Top Insider Buys Highlight for the Week of May 31

Intuitive Surgical

Medical technology companies Intuitive Surgical and Medtronic could feel the pressure as President Donald Trump ratchets up tariffs on Mexican imports, beginning June 10, an analyst says.
The post Medtech Stocks Hit The Brakes As Trump Proposes Mexican Tariffs appeared first on Investor's Business Daily.

Medtech Stocks Hit The Brakes As Trump Proposes Mexican Tariffs

The launch of the SelectSite catheter is in line with Medtronic's (MDT) goal to expand its cardiac care portfolio.

Medtronic Receives FDA Nod for SelectSite Catheter System

Abbott Labs

Autodesk

Cigna

Salesforce

Humana

Intel

Microsoft

NVIDIA

Texas Instruments

To show how business can and must cultivate a Culture of Health, JUST Capital has released new analysis, with support from Robert Wood Johnson Foundation, evaluating how companies perform on core issues of community health.

The Companies Leading On Health For Communities And Families

Medtronic recently reported its Q4 fiscal 2019 results, which were above our estimates, led by the Restorative Therapies Group. This note details the company’s Q4 performance, and Trefis’ forecasts for the full fiscal 2020.

How Did Medtronic Fare In Q4, And What Can We Expect From Fiscal 2020?

Kroger

Realty Income Corp

Starbucks

Target

June is going to be a fun month, as there are a lot of names that are expected to announce an increase.

Expected Dividend Increases In June 2019

Deere & Company

The Zacks Research Daily presents the best research output of our analyst team.

Top Stock Reports for Medtronic, TJX Companies & Deere

Shares of medical device maker Medtronic rose 3.2% after the company reported results for the fiscal fourth quarter that beat profit forecasts and gave better-than-expected guidance for fiscal 2020.

Surgical robot sales lift Medtronic

Medtronic plc (MDT) CEO Omar Ishrak on Q4 2019 Results - Earnings Call Transcript

Best Buy

Trade Conflict Escalates

Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.

Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises

Medtronic (MDT) delivered earnings and revenue surprises of 5.48% and 0.46%, respectively, for the quarter ended April 2019. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Surpasses Q4 Earnings and Revenue Estimates

Medtronic earnings topped fiscal Q4 views as sales unexpectedly edged higher. Shares of the medical products giant rose modestly.

Medtronic Earnings Top; Stock Rises

Medtronic Plc. said Thursday it had net income of $1.172 billion, or 87 cents a share, in its fiscal fourth quarter to April 26, down from $1.460 billion, or $1.07 a share, in the year-earlier period.

Medtronic tops estimates for fiscal fourth quarter

Medtronic reported a nearly 20% drop in quarterly profit on Thursday, hurt by lower sales in its cardiac and vascular business that makes heart valves and stents.

Medical device maker Medtronic posts 20% fall in quarterly profit

Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.

Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?

We are upbeat about Medtronic's (MDT) successful execution of growth strategies such as therapy innovation, globalization and increase in economic value.

Medtronic (MDT) to Report Q4 Earnings: Will It Top Estimates?

The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.

Medtronic (MDT) Launches Telescope Guide Extension Catheter

According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.

Medtronic to Acquire Titan Spine for Spine Portfolio Boost

Medtronic (MDT) closed the most recent trading day at $87.33, moving -1.13% from the previous trading session.

News for Medtronic Stock (MDT)